NextCure (NASDAQ:NXTC) Trading Up 13.9%

NextCure Inc (NASDAQ:NXTC)’s stock price was up 13.9% on Wednesday . The company traded as high as $29.87 and last traded at $29.52, approximately 109,912 shares were traded during mid-day trading. An increase of 42% from the average daily volume of 77,425 shares. The stock had previously closed at $25.92.

A number of equities research analysts have issued reports on NXTC shares. Piper Jaffray Companies started coverage on NextCure in a research note on Monday, June 3rd. They set an “overweight” rating and a $26.00 price target for the company. Bank of America started coverage on NextCure in a research note on Tuesday, July 9th. They set a “buy” rating and a $25.00 price target for the company. Morgan Stanley boosted their price target on NextCure from $25.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Finally, Zacks Investment Research downgraded NextCure from a “hold” rating to a “sell” rating in a research note on Wednesday.

The company’s 50 day moving average price is $20.73. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.05 and a quick ratio of 17.05.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.15). The business had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million. Equities analysts forecast that NextCure Inc will post -1.89 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in NXTC. Victory Capital Management Inc. bought a new position in shares of NextCure during the 2nd quarter valued at approximately $48,000. Tower Research Capital LLC TRC bought a new position in shares of NextCure during the 2nd quarter valued at approximately $96,000. Morgan Stanley bought a new position in shares of NextCure during the 2nd quarter valued at approximately $101,000. Northern Trust Corp bought a new position in shares of NextCure during the 2nd quarter valued at approximately $337,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of NextCure during the 2nd quarter valued at approximately $386,000. Institutional investors and hedge funds own 15.32% of the company’s stock.

NextCure Company Profile (NASDAQ:NXTC)

There is no company description available for NextCure Inc

Further Reading: What is the Quick Ratio?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.